Opus Genetics
IRD
35 hedge funds and large institutions have $10.8M invested in Opus Genetics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 10 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
90% more capital invested
Capital invested by funds: $5.69M → $10.8M (+$5.1M)
25% more call options, than puts
Call options by funds: $35K | Put options by funds: $28K
1.16% more ownership
Funds ownership: 13.73% → 14.89% (+1.2%)
5% less funds holding
Funds holding: 37 → 35 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$699K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$219K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$100K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.6K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$52.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$60K |
| 2 |
Millennium Management
New York
|
-$49K |
| 3 |
Renaissance Technologies
New York
|
-$45.8K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$42K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$39K |
IRD Hedge Fund Activity: Q4 2022 in Review
35 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2022, worth a combined $10.8M — up 90% from $5.69M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IRD and 9 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 11 added.
The largest buyer was Rice Hall James & Associates, adding an estimated $699K. The largest seller was Ameriprise, exiting entirely with an estimated $60K sold.
- 35 institutional investors held Opus Genetics (IRD) as of Q4 2022, down from 37 in Q3 2022.
- Funds reported $10.8M of Opus Genetics stock for Q4 2022, up 90% quarter-over-quarter.
- 9 funds opened new Opus Genetics positions in Q4 2022 and 10 closed out, a net change of -1 holder.
- The largest Opus Genetics buyer in Q4 2022 was Rice Hall James & Associates, an estimated $699K added.
- The largest Opus Genetics seller in Q4 2022 was Ameriprise, an estimated $60K sold.
Based on aggregated 13F filings for Q4 2022.